| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 322.77 | 7.7% |
| Total Income | 325.32 | 7.8% |
| Expenditure | 282.99 | 2.9% |
| PBT | 42.34 | 31.0% |
| Net Profit | 31.48 | 32.6% |
| OPM | 2.34% | 5.28pp |
| NPM | 9.67% | 3.56pp |
| EPS | 6.11 | 32.7% |
Metropolis Healthcare’s PAT up by 15.3% in Q3FY25
05 Feb 2025 · 5 Feb 2025, 12:27 am
Summary
Metropolis Healthcare Limited, India's second-largest pathology laboratory chain, announced its unaudited consolidated financial results for the quarter ended December 31, 2024. The company reported a 15.3% YoY increase in Profit After Tax (PAT) in Q3FY25. EBITDA and PAT margins stood at 22.20% and 9.8% respectively. The growth was driven by high operating leverage, significant growth in Revenue Per Test (RPT), and consistent double-digit growth in B2B revenue. The company is focusing on high-value offerings, expanding its presence in North India, and strengthening its oncology and molecular diagnostics portfolio.
Key Highlights
- 1
PAT up by 15.3% in Q3FY25
- 2
EBITDA grows 17.8% in 9MFY25
- 3
Significant growth in Revenue Per Test (RPT)
- 4
B2B revenue grew 10% YoY in Q3FY25
- 5
TruHealth revenue grew 25% YoY in Q3FY25
Management Comments
Ameera Shah
The diagnostics industry is undergoing a paradigm shift towards personalized medicine, genomics-driven testing, and preventive healthcare, fueled by advancements in molecular diagnostics, Al, and next-generation sequencing. At Metropolis, we remain at the forefront of this transformation, leveraging deep scientific expertise and consumer insights to drive innovation and expand access to cutting-edge diagnostics. Our strategic acquisition of Core Diagnostics is a pivotal step in this direction, strengthening our oncology and molecular diagnostics portfolio and reinforcing our commitment to becoming India’s leading cancer testing provider. As part of our long-term strategy, we are expanding our presence in North India through a ‘string of pearls’ approach, focusing on acquiring high-performing B2C businesses that are leaders in their cities, with strong EBITDA, ROCE, and cash flows. This strategy will enhance our capabilities and deepen our footprint in the region, driving long-term value creation and solidifying Metropolis’ leadership in the evolving diagnostics landscape.
Informational and educational content only. Not investment advice.